Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

"Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

EMA committee recommends approval of Sanofi & Regeneron’s Dupixent to treat eosinophilic esophagitis in children as young as 1 year old: Paris Monday, September 23, 2024, 11:00 ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

AM(IST)on Monday in an upbeat market. Glenmark Pharmaceuticals Ltd.(up 6.99 per cent), Mankind Pharma Ltd.(up 3.47 per cent), ...

"It gives me unique insight into an individual's [AFib]; I'm excited to use this new technology for my patients." Sanofi's ...

Novo Nordisk’s chief executive is preparing for a showdown next week with progressive firebrand Bernie Sanders over the high ...

The RWEsearch Virtual Annual Summit 2024 united a global audience and 45+ experts, driving collaboration and innovation in Real World Evidence. Purav Gandhi Healthark Wellness Solutions LLP +91 ...

The study was an investigator-initiated trial supported by Sanofi. Haluzik has previously consulted and given lectures for Sanofi, Eli Lilly and Company, Novo Nordisk, AstraZeneca, Boehringer ...